SFRP4 Human Pre-designed siRNA Set A contains three designed siRNAs for SFRP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFRP5 Human Pre-designed siRNA Set A contains three designed siRNAs for SFRP5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFSWAP Human Pre-designed siRNA Set A contains three designed siRNAs for SFSWAP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFTA2 Human Pre-designed siRNA Set A contains three designed siRNAs for SFTA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFTPA1 Human Pre-designed siRNA Set A contains three designed siRNAs for SFTPA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFTPA2 Human Pre-designed siRNA Set A contains three designed siRNAs for SFTPA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFTPB Human Pre-designed siRNA Set A contains three designed siRNAs for SFTPB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFTPC Human Pre-designed siRNA Set A contains three designed siRNAs for SFTPC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFTPD Human Pre-designed siRNA Set A contains three designed siRNAs for SFTPD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFXN1 Human Pre-designed siRNA Set A contains three designed siRNAs for SFXN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFXN2 Human Pre-designed siRNA Set A contains three designed siRNAs for SFXN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFXN3 Human Pre-designed siRNA Set A contains three designed siRNAs for SFXN3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFXN4 Human Pre-designed siRNA Set A contains three designed siRNAs for SFXN4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SFXN5 Human Pre-designed siRNA Set A contains three designed siRNAs for SFXN5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGCA Human Pre-designed siRNA Set A contains three designed siRNAs for SGCA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGCB Human Pre-designed siRNA Set A contains three designed siRNAs for SGCB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGCD Human Pre-designed siRNA Set A contains three designed siRNAs for SGCD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGCE Human Pre-designed siRNA Set A contains three designed siRNAs for SGCE gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGCG Human Pre-designed siRNA Set A contains three designed siRNAs for SGCG gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGCZ Human Pre-designed siRNA Set A contains three designed siRNAs for SGCZ gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGF29 Human Pre-designed siRNA Set A contains three designed siRNAs for SGF29 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGF29-IN-1 (Compound Cpd_DC60) is a selective inhibitor for Spt-Ada-Gcn5 acetyltransferase (SAGA)–associated factor 29 (SGF29)-Tudor domain. SGF29-IN-1 exhibits activity against leukemia[1].

SGF29-IN-1 (Compound Cpd_DC60) is a selective inhibitor for Spt-Ada-Gcn5 acetyltransferase (SAGA)–associated factor 29 (SGF29)-Tudor domain. SGF29-IN-1 exhibits activity against leukemia[1].

SGF29-IN-1 (Compound Cpd_DC60) is a selective inhibitor for Spt-Ada-Gcn5 acetyltransferase (SAGA)–associated factor 29 (SGF29)-Tudor domain. SGF29-IN-1 exhibits activity against leukemia[1].

SGF29-IN-1 (Compound Cpd_DC60) is a selective inhibitor for Spt-Ada-Gcn5 acetyltransferase (SAGA)–associated factor 29 (SGF29)-Tudor domain. SGF29-IN-1 exhibits activity against leukemia[1].

SGIP1 Human Pre-designed siRNA Set A contains three designed siRNAs for SGIP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGK1 Human Pre-designed siRNA Set A contains three designed siRNAs for SGK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sgk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sgk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sgk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sgk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGK2 Human Pre-designed siRNA Set A contains three designed siRNAs for SGK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGK3 Human Pre-designed siRNA Set A contains three designed siRNAs for SGK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sgk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sgk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGK3 Rat Pre-designed siRNA Set A contains three designed siRNAs for SGK3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGMS1 Human Pre-designed siRNA Set A contains three designed siRNAs for SGMS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGMS2 Human Pre-designed siRNA Set A contains three designed siRNAs for SGMS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGO1 Human Pre-designed siRNA Set A contains three designed siRNAs for SGO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGO2 Human Pre-designed siRNA Set A contains three designed siRNAs for SGO2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGP8 (IAVPGEVA) is an octopeptide derived from the hydrolysis of soybean 11S globulin. SGP8 (IAVPGEVA) has the role of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway. SGP8 (IAVPGEVA) has the ability to inhibit the non-alcoholic steatohepatitis (NASH) [1].

SGPL1 fluorogenic substrate is the fluorogenic substrate of sphingosine-1-phosphate lyase (SGPL1) that can be used to measure the activity of SGPL1[1].

SGPL1 Human Pre-designed siRNA Set A contains three designed siRNAs for SGPL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGPP1 Human Pre-designed siRNA Set A contains three designed siRNAs for SGPP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGPP2 Human Pre-designed siRNA Set A contains three designed siRNAs for SGPP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas[1].

SGSH Human Pre-designed siRNA Set A contains three designed siRNAs for SGSH gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.